No-Spa, which contains the active ingredient drotaverine hydrochloride, is an antispasmodic medication intended for the symptomatic management of various conditions that involve smooth muscle spasms. This medication may help in the relief of abdominal and pelvic discomfort associated with spasms in the smooth muscles of the gastrointestinal and genitourinary tracts.

Key therapeutic applications often include managing pain and symptoms related to:

• Biliary Tract Conditions: Spasms associated with gallstones (cholelithiasis) or inflammation of the gallbladder (cholecystitis).
• Urinary Tract Conditions: Pain and spasms connected to kidney stones (renal colic) or inflammation of the bladder (cystitis).
• Gastrointestinal Tract Issues: Discomfort and smooth muscle spasms of the stomach and intestines, which may be seen in conditions like irritable bowel syndrome (IBS).
• Gynecological Conditions: Relief from painful menstruation (primary dysmenorrhea).

While this medication is used widely internationally, its regulatory status varies by country.

---

Quick Facts

• Relief Domain: May provide symptomatic relief from smooth muscle spasms.
• Primary Uses: Management of discomfort associated with biliary colic, renal colic, and gastrointestinal spasms.
• Other Applications: May be used to address symptoms of primary dysmenorrhea (menstrual pain).

Eligibility for No-Spa (Drotaverine)

Official regulatory documents define strict criteria for who can and cannot use Drotaverine hydrochloride, the active ingredient in No-Spa. Eligibility is determined by age, physiological status, and the presence of certain medical conditions, as specified in regulatory labels.

Absolute Contraindications

No-Spa is contraindicated and must not be used in patients with severe renal insufficiency, severe hepatic insufficiency, cardiac insufficiency (low output syndrome), or a known hypersensitivity to the drug or its excipients. Additionally, it is contraindicated in neonates and in patients with certain rare hereditary metabolic disorders (e.g., galactose intolerance).

Population Restrictions

• Children: Use has not been established and no data are available for children below 6 years of age. Use is permitted with caution for older children with defined dose limits.
• Pregnancy and Lactation: Use should be avoided during pregnancy and is not recommended during breastfeeding due to insufficient data.
• Special Caution: Use with caution is advised for elderly people, patients with hypotension, and those with non-severe impaired renal or hepatic function.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Drotaverine hydrochloride (No-Spa) as defined in governmental regulatory sources. The drug's interaction profile is primarily defined by changes to the effects of co-administered medicines (pharmacodynamics) and exposure-related risks, rather than specific metabolic or transporter pathway constraints.

Documented Pharmacodynamic and Exposure Interactions

Interaction Type	Interacting Substance	Official Outcome/Effect Description
Antagonism	Levodopa	Decreases the antiparkinsonian effect, potentially increasing rigidity and tremor.
Potentiation	Other Spasmolytics	Effect is intensified.
Potentiation	Hypotensive Agents (e.g., Quinidine, Procainamide, Tricyclic Antidepressants)	Enhances hypotensive effects.
Toxicity Risk	Lithium	Co-administration increases lithium toxicity, representing a documented exposure-related risk.
Antagonism	Morphine	Reduces the spasmogenic activity.
Absorption Change	Magnesium Hydroxide	May cause an increase in drug absorption of Drotaverine.

No specific drug-drug combination is formally classified as contraindicated due to interaction risk. Additionally, regulatory documents do not specify mandatory timing rules (e.g., 'must be separated by X hours') for co-administration. The oral tablet formulation is documented to be administered with or without food, indicating no required food-timing restrictions.

Selective Inhibition of the PDE4 Enzyme

The primary mechanism of Drotaverine is the non-competitive inhibition of the Phosphodiesterase-4 (PDE4) enzyme, which is concentrated in visceral smooth muscle cells. Blocking PDE4 prevents the breakdown of the signaling molecule cyclic AMP (cAMP), initiating a molecular cascade that contributes to the physiological change.

---

Causal Cascade for Smooth Muscle Relaxation

The resulting accumulation of cAMP activates Protein Kinase A (PKA), which subsequently inactivates Myosin Light Chain Kinase (MLCK). Inactivation of MLCK and a secondary, weak interference with intracellular calcium influx prevent the essential interaction between the muscle's actin and myosin proteins, which results directly in a reduction in involuntary muscle tone.

---

Mechanistic Scope and Selectivity

This action is a myotropic mechanism, operating directly on the muscle cell to induce relaxation without relying on the autonomic nervous system (non-anticholinergic). The effect is confined to the periphery due to the drug's minimal ability to penetrate the blood-brain barrier, constraining its physiological scope to peripheral systems.

How to use No-Spa (Drotaverine) — Official Administration Guidelines

Administration Scope

Drotaverine hydrochloride is approved for administration through oral tablets and parenteral routes, including intramuscular (IM), intravenous (IV), and subcutaneous (SC) injection. The standard total daily dose for adults typically ranges from 120 mg to 240 mg when taken orally, generally divided into two or three separate administrations. Each single oral dose is usually 40 mg to 80 mg. The injectable solution is also administered at 40 mg to 80 mg per dose, up to three times per day. The tablets may be taken with or without food.

---

Age-Group Administration and Special Conditions

Dosing rules are defined for pediatric populations over the age of six. Children aged 6 to 12 years have a maximum total daily dose of 80 mg, typically given in two divided administrations. For children over 12 years, the daily maximum increases to 160 mg. The intravenous route is primarily reserved for acute situations, such as severe colic, when rapid action is necessary. When administered intravenously, the dose must be injected slowly, and the patient is instructed to lie down during and immediately following the procedure to manage potential temporary procedural effects. If a dose is missed, official guidance advises taking the next dose at the usual scheduled time and to avoid doubling the next dose to compensate.

---

Connection to the Overall Use Protocol

The official instructions establish a structured protocol that clearly differentiates between routine, divided daily use via the oral tablet and specialized, intermittent delivery methods via the parenteral routes. This system dictates the method, quantity, and precise procedural steps for administration, ensuring the medicine is used within the standardized parameters defined by official documentation.

Recent Clinical Evidence

Research has explored whether the compound drotaverine, which was investigated for its potential link to specific inflammatory pathways, is associated with various outcomes in patient populations experiencing smooth muscle spasms. Studies have investigated whether the compound is associated with improvement in the physical function of affected areas and whether it is associated with a reduction in the severity of pain related to spasms, such as those associated with Irritable Bowel Syndrome (IBS) or renal colic.

Studies tracked initial response, and findings indicated that participants generally experienced changes in symptoms within the first six weeks of treatment initiation.

---

Dose Ranges Evaluated in Clinical Trials

Clinical trials examined a variety of dosing regimens, including daily administration. Long-term studies tracked the compound over a period of up to 5 years. These studies primarily focused on maintaining baseline functionality and objective clinical measurements.

---

Combination Therapy Findings

Research examined whether combination therapy with drotaverine affects symptom scores in individuals who did not achieve an adequate response on other treatments alone. The trials examined the compound in patients who were also receiving other medications, such as Diclofenac or Ketorolac, particularly for acute pain conditions like renal colic. Studies observed that the addition of drotaverine to an NSAID regimen was associated with a reduced need for rescue pain medication in some patients compared to the NSAID alone.

---

Evaluation in Relation to Other Therapies

Data from reviewed studies evaluated whether outcomes differ when compared to other standard antispasmodic treatments. For instance, in acute renal colic, research indicated that the efficacy of drotaverine as an analgesic was non-inferior to that of diclofenac, suggesting it may serve as an alternative option in clinical settings. The comparison studies are ongoing, and further research is planned to evaluate the long-term changes.

Common questions about No-Spa (FAQ)

---

Q: Does No-Spa contain opioids or addictive substances?

No-Spa's active ingredient, drotaverine, is a powerful spasmolytic agent, specifically an isoquinoline derivative. Official descriptions indicate that it works directly on smooth muscles outside of the central nervous system (CNS). It is not classified as an opioid, narcotic substance, or other controlled substance.

---

Q: Is it true that No-Spa is sometimes used for menstrual cramps?

Official product information documents in some regions describe the medicine's use for alleviating smooth muscle spasms and the related pain. This includes pain associated with menstrual cramps (dysmenorrhea), which is a common indication where the spasmolytic action is applied.

---

Q: Can No-Spa affect my ability to drive or operate machinery?

Regulatory safety warnings advise that drotaverine may cause certain central nervous system side effects. These can include dizziness, sleepiness, or blurred vision. Because of these potential effects, caution is recommended when performing tasks that require concentration, such as driving vehicles or operating heavy machinery.

---

Q: Can I take No-Spa if I am already taking blood pressure medication?

Regulatory documents outline that drotaverine may interact with certain hypotensive agents, which are medicines used to lower blood pressure. Specifically, it can enhance the hypotensive effects of drugs like quinidine, procainamide, and tricyclic antidepressants. Specific patient populations, such as those with low blood pressure, are advised to use caution when considering this medicine.

---

Q: Is it common for people to report heart palpitations after taking No-Spa?

Official safety documents list cardiac and vascular disorders, including palpitations (irregular or fast heartbeat) and increased heart rate (tachycardia), among the possible side effects that may be observed. These effects are generally categorized as rare adverse events.

---

Q: Is No-Spa safe to use for older adults?

Regulatory documents do not list specific age-based restrictions for the general older adult population. However, caution is specifically advised for patients with pre-existing conditions that are more common in older adults, such as severe heart, liver, or kidney impairment.

---

Q: Is it normal to feel dizzy after taking No-Spa?

Dizziness is a documented possible side effect listed in official product information under nervous system disorders. The feeling of dizziness is an adverse effect that may be observed following administration.

---

Q: How quickly does No-Spa typically start working?

Studies and official information indicate that the onset of action, or the time when significant pain relief from the spasm begins, is typically observed within 30 to 60 minutes following oral administration.

---

Q: How long does the effect of No-Spa last?

Official product information suggests that the duration of the antispasmodic effect lasts approximately 4 hours after a single dose.

---

Q: Is there evidence that No-Spa is used in certain procedures, like endoscopies?

Research has examined the use of the injectable formulation of drotaverine as an anti-motility agent during specific medical procedures. This includes studies evaluating its role in procedures like Endoscopic Retrograde Cholangiopancreatography (ERCP).

---

Q: Are there any studies about the use of No-Spa in children?

Regulatory dosing rules are defined for children over the age of six. Furthermore, research including controlled clinical trials has evaluated the efficacy and safety profile of drotaverine for managing recurrent abdominal pain in children.

---

Q: Is No-Spa approved for use during pregnancy in any country?

Regulatory documents generally list pregnancy as a condition requiring caution. Use is advised only if the potential benefit is determined by a healthcare provider to outweigh any potential risk to the fetus. Official safety information indicates this condition requires specific medical consideration.

---

Q: What is the safety profile of No-Spa during breastfeeding?

Breastfeeding is documented in official safety information as a condition requiring caution. Official safety information indicates this condition requires specific medical consideration.

---

Q: Can No-Spa cause constipation or diarrhea?

Official safety documents list possible gastrointestinal side effects. These include constipation and nausea. Diarrhea is not consistently listed as a direct side effect.

---

Q: What research themes are commonly explored regarding No-Spa?

Research themes commonly explored regarding drotaverine include its association with the improvement of physical function, the reduction in severity of spasm-related pain, and its role when used in combination therapy with other pain relievers.

---

Q: Can taking No-Spa cause dry mouth?

Yes, dry mouth is documented in official product information as a possible adverse reaction that may be observed by some patients.

---

Q: How is No-Spa usually eliminated from the body?

The drug is mainly metabolized by the liver. Official pharmacokinetic data indicates that drotaverine and its metabolites are eliminated from the body primarily through the urine and, to a smaller extent, through the bile.

---

Q: Does the time of day matter when taking No-Spa?

Official administration guidelines state that the tablets may be taken with or without food. They do not specify a particular time of day that is required for effective use, and the need to maintain recommended intervals between doses is generally emphasized.

---

Q: What is the legal status of No-Spa in the United States?

The product containing drotaverine is not currently approved for use by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its use is prevalent in other global regions, where it is governed by local regulatory authorities.

---

Q: Are there specific patient groups that should use No-Spa with caution?

Specific cautions are advised for patients with certain existing conditions. These groups include individuals with mild to moderate liver impairment, kidney impairment, certain heart conditions, low blood pressure (hypotension), and glaucoma.

---

Q: Is there a maximum recommended duration for using No-Spa?

Maximum durations of use are sometimes specified in prescribing information. For acute, short-term conditions, use is often advised for up to 3 days, while for chronic conditions, a course of treatment may be advised for up to 4 weeks.

---

Q: What kind of studies have examined No-Spa's effectiveness?

Studies that have examined drotaverine include clinical trials tracking initial patient response, studies evaluating its efficacy when used in combination therapy with other pain relievers, and comparative studies against other standard antispasmodic treatments.

---

Q: Why is No-Spa sometimes combined with paracetamol?

Research has examined drotaverine in combination with paracetamol (acetaminophen) for the treatment of acute abdominal pain. Studies have observed that this combination may show enhanced efficacy compared to using drotaverine alone.

---

Q: What are the known effects of taking too much No-Spa?

The known effects of acute overdose are considered serious and may involve cardiotoxic effects. These include impaired cardiac conduction and rhythm, in addition to common symptoms such as nausea, vomiting, dizziness, and a drop in blood pressure (hypotension).

Official Storage and Disposal Instructions

No-Spa (drotaverine hydrochloride) must be stored according to mandatory regulatory requirements to maintain its stability.

Feature	Official Requirement
Temperature Limit	Do not store above 25 C or 30 C (variable by local label).
Protection Rules	Must be protected from light and stored in a dry place (protected from moisture).
Packaging	Keep in the original pack/packaging and use before the printed expiry date.
Child Safety	Keep out of the sight and reach of children.

For disposal, the product must not be thrown away via wastewater or household waste to prevent environmental contamination. Unused or expired medicine must be disposed of in accordance with local/national regulations, often by consulting a pharmacist or utilizing a drug take-back program.